Objective-To determine the association of chronic kidney disease and coronary artery calcium (CAC) incidence, and the distribution of lipoproteins across categories of kidney function and their association with CAC risk. Methods and Results-We analyzed data from 2795 participants in the Multi-Ethnic Study of Atherosclerosis with no CAC (calcium score=0) at baseline enrolled at the first Multi-Ethnic Study of Atherosclerosis visit between the years 2000 and 2002. During a median follow-up of 2.4 years, incident calcium (calcium score>0 at follow-up) developed in 12%, 19%, and 27% of participants with a cystatin-c estimated glomerular filtration rate (mL/min per 1.73 m) 2 of ≥90, 60 to 89, and 30 to 59 (P for difference <0.001), respectively. Compared with those with normal kidney function (estimated glomerular filtration rate≥90), adjusted CAC incidence risk ratios, and 95% confidence intervals (CIs) were as follows: 1.26 (95% CI, 1.04-1.52), and 1.56 (95% CI, 1.11-2.20; P trend =0.014) in those with estimated glomerular filtration rate of 60 to 89 and 30 to 59, respectively. These associations were attenuated after adjusting for a characteristic and strongly interrelated lipid phenotype (principal component 1), which was more common in those with chronic kidney disease and characterized by a predominance of triglyceride-rich lipoproteins: CAC incidence risk ratios=1.21 (95% CI, 1.00-1.46) and 1.44 (95% CI, 1.02-2.04; P trend =0.06) in those with estimated glomerular filtration rate 60 to 89 and 30 to 59, respectively, after adjusting for principal component 1. 
C hronic kidney disease (CKD) is strongly and independently associated with clinical atherosclerotic cardiovascular disease (ASCVD). 1 ,2 Yet, the mechanisms leading to this association are poorly understood. 3 In particular, cross-sectional analyses indicate that CKD is not independently associated with a faster progression of atherosclerosis, 3, 4 suggesting that atherosclerosis may not be an important mechanism leading to the known strong association between CKD and clinical cardiovascular events. These studies, however, have been cross-sectional in nature, and reverse-causality 5 may have contributed to obscure the CKD-atherosclerosis relationship.
Dyslipidemias are among the strongest risk factors for ASCVD. [6] [7] [8] Low-density lipoprotein cholesterol (LDL-c) is the basis for risk prediction and the target of lipidlowering therapy. 9, 10 In addition to LDL-c, a particular lipid phenotype of substantial atherogenic potential consists of elevations of triglycerides (TGs) and small dense lowdensity lipoprotein (LDL) particles (small LDL), and reduced high-density lipoprotein cholesterol (HDL-c) levels. 9, 11, 12 Clinical guidelines recommend the measurement of non-HDL cholesterol (non-HDL-c) to estimate the total number of atherogenic particles in plasma, particularly in individuals with hypertriglyceridemia. 9, 10 Recent evidence suggests that abnormal concentrations of atherogenic lipoproteins and lipoprotein subfractions beyond LDL-c, including elevations in small LDL-c and TGs, and reduced levels of large LDL-c and HDL-c, are present in individuals with mild kidney function impairment. 13 The distribution of lipoproteins and lipoprotein subfractions, their correlation, and whether they contribute information to the ASCVD risk across established categories of mild and moderately reduced kidney function remains unknown.
In this study, we used data from the Multi-Ethnic Study of Atherosclerosis (MESA). The objectives of this study were to (1) characterize the association between kidney function and the risk of coronary artery calcium (CAC) as a marker of subclinical atherosclerosis; (2) determine the more typical lipoprotein patterns in MESA-participants with CKD; and to (3) establish whether elevated lipoprotein concentrations contributed information to the CKD-atherosclerosis relationship.
Materials and Methods

Study Population
MESA is a population-based cohort study aimed at determining the factors associated with subclinical cardiovascular disease and its progression; its methods have been described in detail.
14 Briefly, 6814 individuals without clinical cardiovascular disease at baseline were enrolled at 6 clinical sites between the years 2000 and 2002 (examination 1) and followed at 2-year intervals until 2007 (examination 4). A 5th examination was conducted from 2010 to 2011. For this study, we included 2995 participants at the baseline (examination 1) with CAC scores=0, enrolled between the years 2000 to 2002. We excluded participants without a measurement of cystatin-c (n=65) and those with missing values for any of the relevant lipid components (n=99). In addition, because the number of individuals with estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m 2 was small (n=36), they were excluded from the analysis. A total of 2795 individuals (93% of the initial cohort) were included in this study.
Kidney Function
A cystatin-c-based formula was used to estimate the GFR: 127.7×cystatin-c 
Major Lipids, Lipoproteins, and Lipoprotein Subfractions
Total cholesterol, HDL-c, and TG were measured after an overnight fast using standardized enzymatic methods. 16 The Friedewald formula was used to estimate LDL-c. 17 Non-HDL-c was calculated by the difference between total cholesterol and HDL-c. We also calculated the ratio of non-HDL-c to HDL-c. Lipoprotein subfractions were measured using nuclear magnetic resonance spectroscopy. 18 We used the concentrations in nmol/L of the following subfractions according to their size (values in parentheses): large very low-density lipoprotein (VLDL) (>60 nm), medium VLDL (35-60 nm), small VLDL (29-34 nm), intermediate dense LDL (23) (24) (25) (26) (27) (28) , large LDL (20.5-22 nm), small LDL (18-20.4 ), large high-density lipoprotein (HDL, 9.4-14 nm), medium HDL (8.2-9.3 nm), and small HDL (7.3-8.1 nm).
CAC Incidence
The methods for the cardiac CT measurements in MESA have been described in detail elsewhere. 19 Briefly, each participant was scanned twice and the mean calcium score for the 2 scans was calculated. Scans were read independently at a centralized reading center. To ensure comparability across scans over time and from different clinical centers, CAC measurements were calibrated to a phantom probe with established concentrations of calcium. The agreement on the presence of calcified coronary artery plaque between consecutive scans for the same participant was high (κ statistic=0.92). For intraobserver and interobserver agreement, κ values were 0.93 and 0.90, respectively. The intraclass correlation coefficient for continuous calcium measurements in the paired scans was 0.99. Follow-up CAC measurements were performed on ≈50% (randomly selected) of the cohort at visit 2 (years 2002-2004) , and the other 50% at visit 3 (years 2004-2005) .
We defined CAC incidence as the development of a CAC Agatson scores 20 >0 in those with Agatson scores=0 at baseline.
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Kidney Function and Incidence
To determine whether the abnormal concentrations in plasma lipids contributed to explaining, in part, the relationship between kidney function and CAC incidence, we estimated the association of mildly reduced kidney function and CKD relative to normal kidney function, with CAC incidence sequentially adjusting for demographic and established cardiovascular risk factors.
Statistical Analysis
The Fisher exact test and the Kruskal-Wallis test were used to compare categorical and continuous variables across categories of kidney function, respectively. Associations between categories of kidney function and clinical categories of plasma lipids and continuous levels of lipoprotein subfractions were assessed using generalized linear models. Major plasma lipids and lipoproteins (LDL-c, HDLc, and TGs) were modeled independently, and in combination with lipoprotein subfractions using principal component analyses. 22 The latter method is efficient when analyzing a set of highly interrelated variables (lipoproteins and lipoprotein subfractions), as it reduces the initial number of variables to a set of a few uncorrelated principal components that account for most of the variation present in all the original variables.
Assessment of nonlinear relationships was performed by a graphical comparison with a local smoother function, and by comparing linear models to models with second and third degree order polynomials and selecting the model with the lowest Bayesian information criterion. Incidence ratios were estimated using generalized linear models assuming a Poisson distribution with a logarithmic link function and robust variance estimation. Time to the follow-up CAC measurements was entered in these models as an offset term. These models have been shown to be consistent and efficient estimators of incidence ratios in the presence of a common outcome. 23 For comparisons of different lipids and lipoproteins, and their combinations with lipoprotein subfractions with CAC incidence, we scaled the incidence ratios to a standard deviation of their respective concentration. TGs and HDL-c were log-transformed and estimates are presented for a 25% higher concentration. Wald tests for multiplicative interaction were used to compare the associations of lipids, lipoproteins, and their combination with lipoprotein subfractions across categories of kidney function.
All models were adjusted for age (continuous), sex, race, lipidlowering therapy use, presence of diabetes mellitus (normal, impaired fasting glucose, untreated diabetes mellitus, treated diabetes mellitus), hypertension (normal or hypertension if systolic blood pressure≥140 mm Hg or diastolic blood pressure≥90 mm Hg or use of antihypertensive therapy), and urinary albumin to creatinine ratio.
Because systematically excluding individuals on a lipid-lowering therapy may exclude individuals with an unfavorable risk factor profile, we adjusted for lipid therapy use in the main analysis, but conducted sensitivity analyses excluding individuals using a lipidlowering therapy ( Figure I and Table I in the online-only Data Supplement), and imputing their underlying LDL-c untreated value following methods previously published using MESA. 24 In addition, we used a combined serum creatinine and cystatin formula to estimate GFR, 15 and the CAC volume scoring method for defining CAC incidence.
Results
Study Population
Chronic kidney disease (eGFR, 30-59 mL/min per 1.73 m 2 ) was present in 124 (5%) individuals at baseline. Lower kidney function (eGFR, 30-59; Table 1 ) was more prevalent in women, whites, older participants, and in those on lipid-lowering therapy. No significant differences across categories of kidney function were observed for LDL-c or LDL-particles concentrations. Lower kidney function was associated with higher levels of TGs and VLDL particles, and lower levels of HDL-c. The presence of diabetes mellitus was only more common in those with established CKD (eGFR, 30-59) relative to those with normal kidney function. Compared with those with normal kidney function, hypertension was more frequent with a mild reduction in kidney function (eGFR, 60-89 mL/ min per 1.73 m 2 ) and in those with CKD. Incident calcium developed in 12%, 19%, and 27% of participants with a eGFR in mL/min per 1.73m 2 of ≥90, 60 to 89, and 30 to 59 (P for difference <0.001), respectively.
CAC Incidence
The median time from the first to the follow-up scan was 2.40 years (interquartile range=1.65-3.16 years). Of the 2795 participants with calcium scores=0 at baseline, 444 (16%) participants developed CAC Agatston scores>0 at follow-up (incident CAC). The median Agatston score for those with incident CAC was 5.61 (interquartile range=2.33-13.82).
Compared with those with normal kidney function, there was a strong association between a reduction in kidney function and CAC incidence. This association remained significant after accounting for demographic factors and the presence of diabetes mellitus, hypertension, and kidney damage (urinary albumin to creatinine ratio) that are known to cause both CKD and ASCVD. Specifically, the adjusted incidence probabilities of CAC ( Figure 1 ) were 13% (95% CI, 11%-15%), 17% (95% CI, 15%-19%), and 22% (95% CI, 14%-28%), P trend =0.014, in eGFR categories of ≥90, 60 to 89, and 30 to 59, respectively. eGFR categories of 60 to 89 and 30 to 59 were associated with a 26% and 56% greater risk of CAC incidence (incidence ratio=1.26; 95% CI, 1.04-1.52 and incidence ratio=1.56; 95% CI, 1.11-2.20, respectively), compared with the reference eGFR category (≥90 mL/min per 1.73 m 2 ; Table 2 ).
Lipids, Lipoproteins, and Lipoprotein Subfractions
The adjusted concentrations of lipoprotein subfractions measured by nuclear magnetic resonance varied across eGFR categories, and several atherogenic patterns were particularly evident in those with CKD ( Figure 2 , top). Reduced kidney function was significantly associated with progressively higher levels of small LDL and large VLDL particles, and lower concentrations of large LDL and HDL particles (P trend <0.001), suggesting a pattern of elevated concentrations of TG-rich lipoproteins, but not of cholesterol-rich ones. Similarly, whereas the adjusted prevalence of high LDL-c and non-HDL-c was not associated with reduced kidney function (Figure 2 , bottom), the lower 2 categories of kidney function were associated with progressively higher prevalence of hypertriglyceridemia, low HDL-c, and the non-HDL-c to HDL-c ratio, compared with those with normal kidney function. These associations were minimally changed when excluding individuals on lipid-lowering therapy ( Figure I and Table I in the online-only Data Supplement) or when imputing the LDL-c untreated values (data not shown).
Combination of Lipoproteins and Lipoprotein Subfractions
Specific methods for principal component analyses are presented in Tables II through IV in the online-only Data Supplement. Briefly, the first 2 principal components accounted for the majority of the variance in all lipoproteins analyzed. Of these, the first principal component (PC1) reflected a pattern of hypertriglyceridemia and closely matched the lipid patterns observed in Figure 2 , and principal component 2 reflected a pattern of high cholesterol levels. Compared with those with normal kidney function, the lower 2 categories of kidney function were significantly associated with PC1 (P trend <0.001), but not with principal component 2 (P trend =0.36).
CAC Incidence and Lipoproteins in CKD
The associations of TGs, HDL-c, and PC1 with CAC incidence were not significantly different across levels of kidney function (Table 3) , albeit the limited power to test for multiplicative interactions in these relationships. In those with minimally reduced kidney function and in those with established CKD, the magnitude of the associations between PC1 and CAC incidence were at least as strong as those observed for LDL-c.
Although the association of a reduction of kidney function with CAC incidence was minimally attenuated when adjusting for LDL-c and non-HDL-c (Table 4) , there was a similar attenuation in the strength of this association when adjusting for the non-HDL-c to HDL-c ratio, TGs and HDL-c, and PC1, implying that most of the lipid contribution to CAC incidence in those with CKD come from typical elevations in TG-rich lipoproteins observed in these individuals.
Results from sensitivity analyses were consistent with the main findings.
Discussion
This study shows that a reduction in kidney function, and more specifically, CKD, is associated with a longitudinal measure of atherosclerosis (CAC incidence). Furthermore, it shows that the more salient lipoprotein features present in CKD are those of abnormal concentrations in TG-rich lipoproteins (but not of cholesterol-rich ones), and that these lipoproteins are active contributors to the observed higher risk of CAC in those with CKD.
Despite the known strong independent association of CKD with clinical ASCVD, 1,2 mechanisms explaining these associations are lacking. In particular, previous studies of CKD and subclinical atherosclerosis indicate that CKD is not associated with a faster progression of atherosclerosis. 3, 4 We show, in this study, that a reduction in kidney function is associated with a longitudinal measure of atherosclerosis, even after controlling for known confounders. These findings are in sharp contrast with previous MESA analyses, where there was a null association between a reduction in kidney function and the prevalence of CAC. 3 In separate analyses (data not shown), we confirmed these findings.
A plausible explanation for the discrepant results of CKD with CAC incidence and prevalence is that of reverse causality. 5 Given that cardiovascular risk factors such as race, diabetes mellitus, and hypertension are known determinants of CAC, 25 it is possible that observable CAC deposits may precede measurable reductions in kidney function, thus obscuring the associations between kidney function and CAC prevalence. These discrepancies have also been found in previous studies assessing other cardiovascular risk factors with CAC incidence and prevalence 26 in individuals with CKD. Moreover, our findings provide a plausible mechanistic explanation (atherogenesis) to studies that suggest that CKD is a coronary heart disease risk factor equivalent. 27 This study extends previous research done in individuals with mild impairments in kidney function 13 to show that a cluster of lipid findings with elevations of TG-rich lipoproteins characterizing a particular phenotype (PC1) is strongly associated with CKD, is related to CAC incidence across categories of kidney function, and is the dominant lipid pattern contributing to the strong risk of CAC incidence observed in CKD. This is in contrast to the nonsignificant associations of a reduction in kidney function with cholesterol-rich lipoproteins, and the minimal attenuation of the CKD-CAC relationship, after controlling for LDL-c.
Although the results of clinical trials assessing the clinical benefit derived from a reduction in LDL-c levels in individuals with end-stage renal disease have been inconsistent, 28 ,29 the SHARP study found a reduction in the incidence of cardiovascular events in individuals with CKD taking a combination of simvastatin and ezetimibe compared with placebo. 30 It is not known whether the effect seen in SHARP came solely from the observed reduction of LDL-c, or whether the combination of simvastatin and ezetimibe may have been more active at targeting non-LDL-c-related pathways. It has been shown that a combination of atorvastatin and ezetimibe is more effective in increasing HDL-c levels and in reducing TG levels than either molecule alone. 31 More studies are needed to determine whether reductions in the abnormal concentrations of the lipoproteins that are more strongly associated with CKD result in a reduced burden of CVD in these individuals.
The availability of a full spectrum of lipid abnormalities, including lipoprotein subfractions, across kidney function categories in a large and racially diverse cohort is a strength of this study. We have shown that the more salient lipid and lipoprotein subfraction features present in individuals with mildly reduced kidney function and in those with CKD are closely interrelated and represent a cluster of abnormalities, rather than individual alterations signifying a shift from cholesterolcarrying lipoproteins (LDL-c, large LDL, HDL-c) to a phenotype characterized by high levels of TG-carrying lipoproteins (VLDL particles and small HDL) and its correlate small LDL.
The predictive value of this single lipid phenotype seems to be consistent with the results of studies that have found common genetic determinants to lipid alterations. 32, 33 Furthermore, clinical guidelines have used the term atherogenic lipid triad 9 to describe this typical lipid pattern, as well as its potential role in increasing cardiovascular risk. The very similar contributions of PC1 compared with the non-HDL-c to HDL-c to the increased risk of CAC incidence in CKD means that this component adequately captures the alterations of lipids and lipoproteins independently of LDL-c in CKD. Future studies should define whether these lipid abnormalities are associated with clinical cardiovascular disease in individuals with CKD.
There are important limitations of this study that warrant discussion. First, kidney function was not directly measured, but rather estimated with a cystatin-c-based equation measured at one point in time. Thus, a certain degree of misclassification may occur, when stratifying individuals to different kidney function categories. Nonetheless, the cystatin-c-based equation used here has been shown to be a valid and precise estimate of GFR, and our results were consistent, when we used a combined serum creatinine and cystatin-c-based formula. Second, it has been suggested that not all risk factors for CAC are exactly the same as those for clinical CVD. 21 Thus, we cannot directly extrapolate our findings to clinical events. Finally, the small sample size in those with established CKD (eGFR=30-59) does not allow for testing of multiplicative interactions in the association of lipids and CAC incidence across levels of kidney function. Even for LDL-c (whose magnitude seems to be attenuated with decreased kidney function; Table 3 ), the small sample size in those with eGFR 30 to 59 does not allow for making heterogeneity inferences.
In sum, CKD is strongly associated with CAC incidence. Lipid abnormalities characterizing a phenotype with elevations in TG-carrying lipoproteins are more prevalent in individuals with mild reductions in kidney function and moderate CKD, are associated with CAC incidence across categories of kidney function, and contribute information to the risk of CAC incidence in CKD. Whether the incorporation of these lipid abnormalities in individuals with CKD help to explain the DM indicates diabetes mellitus; eGFR, estimated glomerular filtration rate; HDL-c, high-density lipoprotein cholesterol; HTN, hypertension; LDL-c, low-density lipoprotein cholesterol; non-HDL-c, non-HDL cholesterol; PC1, principal component 1; and UACR, urinary albumin to creatinine ratio.
*Adjusted for age (continuous), sex, race, and presence of diabetes mellitus (DM; normal, impaired fasting glucose, untreated diabetes mellitus, treated diabetes mellitus), hypertension (HTN; normal or hypertension if systolic blood pressure≥140 mm Hg or diastolic blood pressure≥90 mm Hg or use of antihypertensive therapy), and urinary albumin to creatinine ratio (UACR).
†Adjusted for demographics, DM, HTN, UACR, and LDL-c. ‡Adjusted for demographics, DM, HTN, UACR, and non-HDL-c. §Adjusted for demographics, DM, HTN, UACR, and non-HDL-c/HDL-c. ||Adjusted for demographics, DM, HTN, UACR, and triglycerides, and HDL-c. ¶Adjusted for demographics, DM, HTN, UACR, and PC-1.
greater burden of cardiovascular disease should be assessed in studies using clinical cardiovascular disease end points.
